Recipharm AB (publ) (RCPHF) Stock Price, News & Analysis

Recipharm AB (publ) provides contract development and manufacturing solutions to the pharmaceutical industry in Sweden, Italy, France, India, Spain, Portugal, Germany, and internationally. It operates through three segments: Manufacturing Steriles & Inhalation, Manufacturing Solids and Others, and Development and Technology. The company manufactures liquid vials and ampoules, lyophilisates, and blow-fill-seal products and inhalation; and tablets, capsules, semi-solids, and non-sterile liquids on behalf of pharmaceutical companies. It also provides supplementary services, such as regulatory, supply chain, active life cycle management, and stability studies and analytical method development services, as well as gateway release and testing services. In addition, the company offers pharmaceutical development services based on various technologies, such as drug substance, drug product, and clinical services to pharmaceutical companies in the drug development phase for new pharmaceuticals; and access to a range of proprietary technologies and intellectual property. Further, it supplies medical devices and veterinary products; and solid, semi-solid, liquid, injectable, and ophthalmic products, as well as serialization services. The company serves various pharma, and research and development companies. The company was founded in 1995 and is headquartered in Stockholm, Sweden.